Performance
Trailing returns
| 1 day |
| -0.51% | |||
| 1 week | +0.46% |
| |||
| 4 week | +3.41% |
| |||
| 3 month | +13.01% |
| |||
| YTD | +21.28% |
| |||
| 1 year | +35.55% |
| |||
| 3 years* | +20.90% |
| |||
| 5 years* | +11.85% |
| |||
| *annualised | |||||
| Best 3-month return | +16.91% | |
| Worst 3-month return | -22.18% |
Morningstar statistics
Morningstar category: Health
| Return | Risk | Rating | |
| 3 years | Average | Low |
 
|
| 5 years | Average | Low |
|
| 10 years | Average | Low |
|
| Overall | Average | Low |
|
Morningstar style Learn more
| Large | |||
| Mid | |||
| Small | |||
| Value | Blend | Growth |
Key statistics
| Total assets | 27,549.23M | |
| Front load | - | |
| Deferred load | - | |
| Expense ratio | 0.30% | |
| Management fee | - | |
| Fund family | Vanguard |
Asset allocation
| Cash | 0.00% | |
| Stocks | 96.17% | |
| Bonds | 0.02% | |
| Other | 3.81% |
Purchase information
| Initial | $0 | |
| Additional | $100 | |
| AIP Initial | $0 | |
| AIP Additional | $100 |
72.05+0.54(0.76%)
May 21, 4:00pm GMT-4
Overall Morningstar RatingTM
Description
The investment seeks long-term capital appreciation. The fund invests at least 80% of its assets in the stocks of companies principally engaged in the development, production, or distribution of products and services related to the health care industry. These companies include, among others, pharmaceutical firms, medical supply companies, and businesses that operate hospitals and other health care facilities. It also considers companies engaged in medical, diagnostic, biochemical, and other research and development activities. The fund may invest up to 50% of its assets in foreign stocks.
Fund filings (PDF) »
Fund filings (PDF) »
Asset manager:
Jean Hynes (Started: May 29, 2008)
Jean Hynes (Started: May 29, 2008)
Risk
| 1 year | 3 years | 5 years | 10 years | ||
| Alpha* | 12.96 | 11.08 | 9.73 | 5.13 | |
| Beta* | 0.70 | 0.55 | 0.61 | 0.60 | |
| Mean annual return | 2.03 | 1.41 | 1.02 | 0.95 | |
| R-squared* | 67.34 | 69.79 | 69.54 | 60.87 | |
| Standard deviation | 10.60 | 10.92 | 15.09 | 12.27 | |
| Sharpe ratio | 2.29 | 1.54 | 0.79 | 0.79 | |
| * Against standard index | |||||
Top 10 holdings
| Security | Net Assets | |
| Merck & Co Inc (MRK) | 6.02% | |
| Amgen Inc (AMGN) | 4.47% | |
| UnitedHealth Group Inc (UNH) | 4.17% | |
| Forest Laboratories, Inc. (FRX) | 3.80% | |
| Roche Holding AG (RHHVF) | 3.68% | |
| McKesson, Inc. (MCK) | 3.50% | |
| Pfizer Inc (PFE) | 3.46% | |
| Eli Lilly and Company (LLY) | 3.31% | |
| Astellas Pharma, Inc. (4503) | 2.93% | |
| AstraZeneca PLC (AZN) | 2.85% |